메뉴 건너뛰기




Volumn 22, Issue 4, 2008, Pages 430-437

Management of patients with resistant or refractory chronic myelogenous leukemia

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; CYTARABINE; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANILINE DERIVATIVE; NITRILE; NS-187; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

EID: 45549088374     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (5)

References (55)
  • 1
    • 0023717986 scopus 로고
    • Staging and prognosis in chronic myelogenous leukemia
    • Sokal JE, Baccarani M, Russo D, et al: Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49-61, 1988.
    • (1988) Semin Hematol , vol.25 , pp. 49-61
    • Sokal, J.E.1    Baccarani, M.2    Russo, D.3
  • 2
    • 0022350250 scopus 로고
    • Prognostic discrimination among younger patients with chronic granulocytic leukemia: Relevance to bone marrow transplantation
    • Sokal JE, Baccarani M, Tura S, et al: Prognostic discrimination among younger patients with chronic granulocytic leukemia: Relevance to bone marrow transplantation. Blood 66:1352-1357, 1985.
    • (1985) Blood , vol.66 , pp. 1352-1357
    • Sokal, J.E.1    Baccarani, M.2    Tura, S.3
  • 3
    • 0020972981 scopus 로고
    • Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia
    • Bartram CR, de Klein A, Hagemeijer A, et al: Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306:277-280, 1983.
    • (1983) Nature , vol.306 , pp. 277-280
    • Bartram, C.R.1    de Klein, A.2    Hagemeijer, A.3
  • 4
    • 0021346853 scopus 로고
    • Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
    • Groffen J, Stephenson JR, Heisterkamp N, et al: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93-99, 1984.
    • (1984) Cell , vol.36 , pp. 93-99
    • Groffen, J.1    Stephenson, J.R.2    Heisterkamp, N.3
  • 5
    • 0025348013 scopus 로고
    • Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
    • Lugo TG, Pendergast AM, Muller AJ, et al: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082, 1990.
    • (1990) Science , vol.247 , pp. 1079-1082
    • Lugo, T.G.1    Pendergast, A.M.2    Muller, A.J.3
  • 6
    • 33747154547 scopus 로고    scopus 로고
    • Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
    • Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006.
    • (2006) Blood , vol.108 , pp. 1809-1820
    • Baccarani, M.1    Saglio, G.2    Goldman, J.3
  • 7
    • 34247248807 scopus 로고    scopus 로고
    • Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure
    • Kantarjian H, O'Brien S, Talpaz M, et al: Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 109:1556-1560, 2007.
    • (2007) Cancer , vol.109 , pp. 1556-1560
    • Kantarjian, H.1    O'Brien, S.2    Talpaz, M.3
  • 8
    • 0029947186 scopus 로고    scopus 로고
    • Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    • Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996.
    • (1996) Nat Med , vol.2 , pp. 561-566
    • Druker, B.J.1    Tamura, S.2    Buchdunger, E.3
  • 9
    • 15444350807 scopus 로고    scopus 로고
    • Selective inhibition of cell proliferation and BCR, ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
    • Beran M, Can X, Estrov Z, et al: Selective inhibition of cell proliferation and BCR, ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148), Clin Cancer Res 4:1661-1672, 1998.
    • (1998) Clin Cancer Res , vol.4 , pp. 1661-1672
    • Beran, M.1    Can, X.2    Estrov, Z.3
  • 10
    • 0031409736 scopus 로고    scopus 로고
    • Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis
    • Gambacorti-Passerini C, le Coutre P, Mologni L, et al: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380-394, 1997.
    • (1997) Blood Cells Mol Dis , vol.23 , pp. 380-394
    • Gambacorti-Passerini, C.1    le Coutre, P.2    Mologni, L.3
  • 11
    • 10744233716 scopus 로고    scopus 로고
    • Imatinib compared With interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared With interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003.
    • (2003) N Engl J Med , vol.348 , pp. 994-1004
    • O'Brien, S.G.1    Guilhot, F.2    Larson, R.A.3
  • 12
    • 33748791111 scopus 로고    scopus 로고
    • Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study (abstract 6506)
    • 338s
    • Druker B, Guilhot, F, O'Brien S, et al: Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study (abstract 6506). J Clin Oncol 24(18S):338s, 2006.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S
    • Druker, B.1    Guilhot, F.2    O'Brien, S.3
  • 13
    • 33845444046 scopus 로고    scopus 로고
    • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    • Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006.
    • (2006) N Engl J Med , vol.355 , pp. 2408-2417
    • Druker, B.J.1    Guilhot, F.2    O'Brien, S.G.3
  • 14
    • 0035810142 scopus 로고    scopus 로고
    • Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
    • Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001.
    • (2001) N Engl J Med , vol.344 , pp. 1038-1042
    • Druker, B.J.1    Sawyers, C.L.2    Kantarjian, H.3
  • 15
    • 4344672552 scopus 로고    scopus 로고
    • Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance
    • Hochhaus A, La Rosee P: Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. Leukemia 18:1321-1331, 2004.
    • (2004) Leukemia , vol.18 , pp. 1321-1331
    • Hochhaus, A.1    La Rosee, P.2
  • 16
    • 0001686739 scopus 로고    scopus 로고
    • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    • Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002.
    • (2002) Cancer Cell , vol.2 , pp. 117-125
    • Shah, N.P.1    Nicoll, J.M.2    Nagar, B.3
  • 17
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001.
    • (2001) Science , vol.293 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3
  • 18
    • 19244366937 scopus 로고    scopus 로고
    • Minimal residual disease in chronic myeloid leukemia
    • Lowenberg B: Minimal residual disease in chronic myeloid leukemia. N Engl J Med 349:1399-1401, 2003.
    • (2003) N Engl J Med , vol.349 , pp. 1399-1401
    • Lowenberg, B.1
  • 19
    • 0038375012 scopus 로고    scopus 로고
    • Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
    • Corbin AS, La Rosee P, Stoffregen EP, et al: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611-4614, 2003.
    • (2003) Blood , vol.101 , pp. 4611-4614
    • Corbin, A.S.1    La Rosee, P.2    Stoffregen, E.P.3
  • 20
    • 0037315281 scopus 로고    scopus 로고
    • Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
    • Gambacorti-Passerini CB, Gunby RH, Piazza R, et al: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4:75-85, 2003.
    • (2003) Lancet Oncol , vol.4 , pp. 75-85
    • Gambacorti-Passerini, C.B.1    Gunby, R.H.2    Piazza, R.3
  • 21
    • 65449137398 scopus 로고    scopus 로고
    • Mutational analysis of chronic myeloid leukemia (CML) clones reveals heightened BCR-ABL1 genetic instability and wild-type BCR-ABL1 exhaustion in patients failing sequential imatinib and dasatinib therapy (abstract 1938)
    • Quintas-Cardama A, Gibbons DL, Kantarjian H, et al: Mutational analysis of chronic myeloid leukemia (CML) clones reveals heightened BCR-ABL1 genetic instability and wild-type BCR-ABL1 exhaustion in patients failing sequential imatinib and dasatinib therapy (abstract 1938). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Quintas-Cardama, A.1    Gibbons, D.L.2    Kantarjian, H.3
  • 22
    • 0034665713 scopus 로고    scopus 로고
    • Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
    • Schindler T, Bornmann W, Pellicena P, et al: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942, 2000.
    • (2000) Science , vol.289 , pp. 1938-1942
    • Schindler, T.1    Bornmann, W.2    Pellicena, P.3
  • 23
    • 21144451094 scopus 로고    scopus 로고
    • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
    • O'Hare T, Waiters DK, Stoffregen EP, et al: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500-4505, 2005.
    • (2005) Cancer Res , vol.65 , pp. 4500-4505
    • O'Hare, T.1    Waiters, D.K.2    Stoffregen, E.P.3
  • 24
    • 15944404601 scopus 로고    scopus 로고
    • The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    • Deininger M, Buchdunger E, Druker B J: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653, 2005.
    • (2005) Blood , vol.105 , pp. 2640-2653
    • Deininger, M.1    Buchdunger, E.2    Druker, B.J.3
  • 25
    • 23344440655 scopus 로고    scopus 로고
    • Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
    • Carter TA, Wodicka LM, Shah NP, et al: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102:11011-11016, 2005.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 11011-11016
    • Carter, T.A.1    Wodicka, L.M.2    Shah, N.P.3
  • 26
    • 0036682301 scopus 로고    scopus 로고
    • Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)
    • Nagar B, Bornmann WG, Pellicena P, et al: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236-4243, 2002.
    • (2002) Cancer Res , vol.62 , pp. 4236-4243
    • Nagar, B.1    Bornmann, W.G.2    Pellicena, P.3
  • 27
    • 0344626925 scopus 로고    scopus 로고
    • A myristoyl/phosphotyrosine switch regulates c-Abl
    • Hantschel O, Nagar B, Guettler S, et al: A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112:845-857, 2003.
    • (2003) Cell , vol.112 , pp. 845-857
    • Hantschel, O.1    Nagar, B.2    Guettler, S.3
  • 28
    • 0037459344 scopus 로고    scopus 로고
    • Mechanisms of autoinhibition and STI-571/ imatinib resistance revealed by mutagenesis of BCR-ABL
    • Azam M, Latek RR, Daley GQ: Mechanisms of autoinhibition and STI-571/ imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112:831-843, 2003.
    • (2003) Cell , vol.112 , pp. 831-843
    • Azam, M.1    Latek, R.R.2    Daley, G.Q.3
  • 29
    • 0037438640 scopus 로고    scopus 로고
    • BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
    • Donato NJ, Wu JY, Stapley J, et al: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690-698, 2003.
    • (2003) Blood , vol.101 , pp. 690-698
    • Donato, N.J.1    Wu, J.Y.2    Stapley, J.3
  • 30
    • 13844251975 scopus 로고    scopus 로고
    • Characterization of AMN 107, a selective inhibitor of native and mutant Bcr-Abl
    • Weisberg E, Manley PW, Breitenstein W, et al: Characterization of AMN 107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129-141, 2005.
    • (2005) Cancer Cell , vol.7 , pp. 129-141
    • Weisberg, E.1    Manley, P.W.2    Breitenstein, W.3
  • 31
    • 33847379510 scopus 로고    scopus 로고
    • Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias
    • Weisberg E, Catley L, Wright RD, et al: Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 109:2112-2120, 2007.
    • (2007) Blood , vol.109 , pp. 2112-2120
    • Weisberg, E.1    Catley, L.2    Wright, R.D.3
  • 32
    • 33745086350 scopus 로고    scopus 로고
    • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    • Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551, 2006.
    • (2006) N Engl J Med , vol.354 , pp. 2542-2551
    • Kantarjian, H.1    Giles, F.2    Wunderle, L.3
  • 33
    • 43549116467 scopus 로고    scopus 로고
    • Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance (abstract 735)
    • Kantarjian H, Hochhaus, A, Cortes, J, et al: Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance (abstract 735). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Kantarjian, H.1    Hochhaus, A.2    Cortes, J.3
  • 34
    • 62649160345 scopus 로고    scopus 로고
    • Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance (abstract 471)
    • le Coutre P, Giles FJ, Apperley J, et al: Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance (abstract 471). Blood 110, 2007.
    • (2007) Blood , vol.110
    • le Coutre, P.1    Giles, F.J.2    Apperley, J.3
  • 35
    • 43549112174 scopus 로고    scopus 로고
    • Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CME-BC) who are resistant or intolerant to imatinib (abstract 1025)
    • Giles F, Larson RA, Kantarjian K, et al: Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CME-BC) who are resistant or intolerant to imatinib (abstract 1025). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Giles, F.1    Larson, R.A.2    Kantarjian, K.3
  • 36
    • 19944428353 scopus 로고    scopus 로고
    • Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-me-thylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
    • Lombardo LJ, Lee FY, Chen P, et al: Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-me-thylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658-6661, 2004.
    • (2004) J Med Chem , vol.47 , pp. 6658-6661
    • Lombardo, L.J.1    Lee, F.Y.2    Chen, P.3
  • 37
    • 3142676436 scopus 로고    scopus 로고
    • Overriding imatinib resistance with a novel ABL kinase inhibitor
    • Shah NP, Tran C, Lee FY, et al: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401, 2004.
    • (2004) Science , vol.305 , pp. 399-401
    • Shah, N.P.1    Tran, C.2    Lee, F.Y.3
  • 38
    • 33745102555 scopus 로고    scopus 로고
    • Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
    • Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541, 2006.
    • (2006) N Engl J Med , vol.354 , pp. 2531-2541
    • Talpaz, M.1    Shah, N.P.2    Kantarjian, H.3
  • 39
    • 29144492198 scopus 로고    scopus 로고
    • BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum anti-tumor activities in vitro and in vivo (abstract 675)
    • Lee F, Lombardo, L, Camuso, A, et al: BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum anti-tumor activities in vitro and in vivo (abstract 675). Proc Am Assoc Cancer Res 46:159, 2005.
    • (2005) Proc Am Assoc Cancer Res , vol.46 , pp. 159
    • Lee, F.1    Lombardo, L.2    Camuso, A.3
  • 40
    • 49249109701 scopus 로고    scopus 로고
    • Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013) (abstract 734)
    • Stone R, Kantarjian H, Baccarani M, et al: Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013) (abstract 734). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Stone, R.1    Kantarjian, H.2    Baccarani, M.3
  • 41
    • 49249109701 scopus 로고    scopus 로고
    • Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005) (abstract 470)
    • Guilhot F, Apperley JF, Kim D, et al: Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005) (abstract 470). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Guilhot, F.1    Apperley, J.F.2    Kim, D.3
  • 42
    • 58649117545 scopus 로고    scopus 로고
    • Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program (abstract 472)
    • Gambacorti C, Cortes J, Kim D, et al: Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program (abstract 472). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Gambacorti, C.1    Cortes, J.2    Kim, D.3
  • 43
    • 62649172099 scopus 로고    scopus 로고
    • Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) (abstract 1035)
    • Jabbour E, Kantarjian H, Atallah E, et al: Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) (abstract 1035). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Jabbour, E.1    Kantarjian, H.2    Atallah, E.3
  • 44
    • 58649121459 scopus 로고    scopus 로고
    • Dasatinib or high-dose imatinib for patients with chronic-phase chronic myeloid leukemia resistant to standard-dose imatinib: 2-year follow-up data from START-R (CA180-017) (abstract 736)
    • Kantarjian H, Rousselot P, Pasquini R, et al: Dasatinib or high-dose imatinib for patients with chronic-phase chronic myeloid leukemia resistant to standard-dose imatinib: 2-year follow-up data from START-R (CA180-017) (abstract 736). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Kantarjian, H.1    Rousselot, P.2    Pasquini, R.3
  • 45
    • 33845806858 scopus 로고    scopus 로고
    • In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
    • Puttini M, Coluccia AM, Boschelli F, et al: In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66:11314-11322, 2006.
    • (2006) Cancer Res , vol.66 , pp. 11314-11322
    • Puttini, M.1    Coluccia, A.M.2    Boschelli, F.3
  • 46
    • 65449178270 scopus 로고    scopus 로고
    • A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib (abstract 168)
    • Cortes J, Kantarjian, H, Baccarani, M, et al: A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib (abstract 168). Blood 108, 2006.
    • (2006) Blood , vol.108
    • Cortes, J.1    Kantarjian, H.2    Baccarani, M.3
  • 47
    • 34548523623 scopus 로고    scopus 로고
    • Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure
    • Quintas-Cardama A, Kantarjian H, O'Brien S, et al: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914, 2007.
    • (2007) J Clin Oncol , vol.25 , pp. 3908-3914
    • Quintas-Cardama, A.1    Kantarjian, H.2    O'Brien, S.3
  • 48
    • 0037093092 scopus 로고    scopus 로고
    • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study
    • Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530-3539, 2002.
    • (2002) Blood , vol.99 , pp. 3530-3539
    • Sawyers, C.L.1    Hochhaus, A.2    Feldman, E.3
  • 49
    • 65449186066 scopus 로고    scopus 로고
    • Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML) (abstract 733)
    • Cores J, Bruemmendorf, T, Kantarjian H, et al: Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML) (abstract 733). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Cores, J.1    Bruemmendorf, T.2    Kantarjian, H.3
  • 50
    • 47649093491 scopus 로고    scopus 로고
    • Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL (abstract 473)
    • Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T, et al: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL (abstract 473). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Gambacorti-Passerini, C.1    Kantarjian, H.2    Bruemmendorf, T.3
  • 51
    • 33846018356 scopus 로고    scopus 로고
    • INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
    • Yokota A, Kimura S, Masuda S, et al: INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 109:306-314, 2007.
    • (2007) Blood , vol.109 , pp. 306-314
    • Yokota, A.1    Kimura, S.2    Masuda, S.3
  • 52
    • 45749104554 scopus 로고    scopus 로고
    • A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors (abstract 469)
    • Kantarjian H, Cortes, J, le Coutre, P, et al: A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors (abstract 469). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Kantarjian, H.1    Cortes, J.2    le Coutre, P.3
  • 53
    • 55949130519 scopus 로고    scopus 로고
    • IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract 25)
    • Hochhaus A, Druker B J, Larson R, et al: IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract 25). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Hochhaus, A.1    Druker, B.J.2    Larson, R.3
  • 54
    • 35248867857 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors for chronic myelogenous leukemia (letter)
    • incl author reply
    • Quintas-Cardama A, Kantarjian H, Cortes J: Tyrosine kinase inhibitors for chronic myelogenous leukemia (letter). N Engl J Med 357:1557-1558 (incl author reply), 2007.
    • (2007) N Engl J Med , vol.357 , pp. 1557-1558
    • Quintas-Cardama, A.1    Kantarjian, H.2    Cortes, J.3
  • 55
    • 43549116467 scopus 로고    scopus 로고
    • Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib (abstract 1036)
    • Kantarjian H, Quintas-Cardama, A, O'Brien, S, et al: Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib (abstract 1036). Blood 110, 2007.
    • (2007) Blood , vol.110
    • Kantarjian, H.1    Quintas-Cardama, A.2    O'Brien, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.